5 July 2022
-
MRD - What will change in the next year?
Multiple Myeloma~myelomaconnect~NDMM~RRMM
EM-93560
13 September 2022
-
Challenges in CLL: How risk stratification can guide the choice of first-line treatment in patients with CLL
challengesincll~CLL
EM-93552
20 September 2022
-
The role of the multidisciplinary team in the management of patients with AL amyloidosis
Amyloidosis~Multiple Myeloma~myelomaconnect
EM-93566
4 October 2022
-
How do we ensure we choose the right treatment for the right patient?
Multiple Myeloma~myelomaconnect~NDMM
EM-93604
25 October 2022
-
What are the key drivers for selecting ideal RRMM patients for treatment with bispecific antibodies?
Multiple Myeloma~myelomaconnect~RRMM
EM-93607
2 November 2022
-
Challenges in NHL: state of the art management of MCL
challengesinnhl~NHL
EM-92747
8 November 2022
-
Challenges in CLL: Continuous, time-limited, or MRD-guided therapy
challengesincll~CLL
EM-92734
9 November 2022
-
INSIDER: Highlights from the 11th International Workshop on Waldenström’s Macroglobulinemia
challengesinnhl~NHL
EM-96531
15 November 2022
-
A focus on standard risk patients with MM and the roadmap to cure
Multiple Myeloma~myelomaconnect~NDMM
EM-93617
16 November 2022
-
What are the key drivers for selecting ideal RRMM patients for treatment with CAR T-cell therapy?
Multiple Myeloma~myelomaconnect~RRMM
EM-93624